HIA
ALXN

Harbor Investment Advisory’s Alexion Pharmaceuticals ALXN Stock Holding History

Harbor Investment Advisory’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-39
Closed -$7K – 1378
2021
Q2 		$7K Hold
39
– – ﹤0.01% 1074
2021
Q1 		$6K Sell
39
-680
-95% -$105K ﹤0.01% 1064
2020
Q4 		$112K Buy
719
+176
+32% +$22.6K 0.02% 429
2020
Q3 		$62K Buy
543
+259
+91% +$27.9K 0.01% 455
2020
Q2 		$32K Sell
284
-901
-76% -$95.7K 0.01% 528
2020
Q1 		$106K Sell
1,185
-151
-11% -$14.8K 0.03% 307
2019
Q4 		$144K Buy
+1,336
New +$143K 0.03% 295

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Harbor Investment Advisory's ALXN Position: Q3 2021 in Review

Harbor Investment Advisory sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 39 shares — an estimated $7K sold.

Harbor Investment Advisory first reported a position in ALXN in Q4 2019 and held it in 7 quarters. The position peaked at $144K in Q4 2019. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Harbor Investment Advisory reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Harbor Investment Advisory sold 39 Alexion Pharmaceuticals shares in Q3 2021, an estimated $7K.
  • Harbor Investment Advisory first reported a position in Alexion Pharmaceuticals in Q4 2019 and held it in 7 quarters.
  • Harbor Investment Advisory's Alexion Pharmaceuticals position peaked at $144K in Q4 2019.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Harbor Investment Advisory's 13F filing for Q3 2021, filed 12 Oct 2021.